Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $8.7 million.

  • Niagen Bioscience's Accumulated Expenses fell 929.94% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 929.94%. This contributed to the annual value of $7.8 million for FY2024, which is 1765.51% down from last year.
  • Latest data reveals that Niagen Bioscience reported Accumulated Expenses of $8.7 million as of Q3 2025, which was down 929.94% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Accumulated Expenses registered a high of $10.5 million during Q1 2024, and its lowest value of $5.6 million during Q2 2021.
  • Over the past 5 years, Niagen Bioscience's median Accumulated Expenses value was $8.1 million (recorded in 2022), while the average stood at $8.0 million.
  • In the last 5 years, Niagen Bioscience's Accumulated Expenses surged by 3607.16% in 2023 and then plummeted by 1765.51% in 2024.
  • Over the past 5 years, Niagen Bioscience's Accumulated Expenses (Quarter) stood at $6.5 million in 2021, then rose by 13.21% to $7.3 million in 2022, then grew by 29.39% to $9.5 million in 2023, then fell by 17.66% to $7.8 million in 2024, then grew by 11.3% to $8.7 million in 2025.
  • Its Accumulated Expenses was $8.7 million in Q3 2025, compared to $7.4 million in Q2 2025 and $9.0 million in Q1 2025.